endo - I liked the CEO's discussion about how sales of SpyScope should benefit by the existing placements they already have in 500+ hospitals - the finance people at these hospitals are already aware of the cost/benefit that Spy brings to their operating rooms and I assume the SpyScope is not that more expensive than a traditional scope, so it will simply fall into the replacement budget decisions - therefore, sales should ramp fairly quickly and not require a huge sales team to launch/market.